Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
It is not the subject of a USP or NF monograph, is not a component of any FDA-approved drug product, and does not appear on the 503A bulk drug substance list for compounding pharmacies
Across trials, 30% to 80% of patients achieve hemoglobin A1c targets below 7%, with semaglutide often producing the greatest reductions
Why Does the Wegovy Injection Hurt
US$ 25.87
US$ 27.98
US$ 20.21
